Addition of anti-PD-1 therapy concurrently with mmHERA-CD40L and RT to tumor bearing mice resulted in no additional therapeutic benefit compared to animals which received RT and mmHERA-CD40L (Figure 6B, Supplementary Figure 7B). The gene discussed is CD40LG; the disease is neoplasm.